Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 3/20 | 0.70 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | FABP3 | P05413 | 1/20 | 0.44 |
| ▸ | FABP4 | P15090 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | RAF1 | P04049 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16814951 | 1.00 | NCF1 (0.70) | NCF1KEAP1MAPK1NPC1GAA | |
| SCHEMBL111729 | 0.98 | NCF1 (0.72) | NCF1KEAP1MAPK1NPC1GAA | |
| SCHEMBL16814882 | 0.94 | NCF1 (0.77) | NCF1KEAP1MAPK1NPC1GAA | |
| SCHEMBL27834649 | 0.90 | NCF1 (0.71) | NCF1KEAP1KMT2AALDH1A1KDM4E | |
| SCHEMBL10558443 | 0.85 | KEAP1 (0.53) | NCF1KEAP1MAPK1NPC1GAA | |
| Phenylpiperazine SCHEMBL8135281 | 0.83 | ADRB1 (0.56) | NCF1 | |
| SCHEMBL111234 | 0.83 | NCF1 (1.00) | NCF1KEAP1MAPK1KMT2AALDH1A1 | |
| SCHEMBL27585360 | 0.82 | NCF1 (0.58) | NCF1KEAP1GAAKMT2AALDH1A1 | |
| SCHEMBL6514775 | 0.82 | KEAP1 (0.53) | NCF1KEAP1MAPK1NPC1GAA | |
| SCHEMBL16814930 | 0.81 | L3MBTL1 (0.54) | NCF1HRH3ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0427765-B1 | ALKOXY-4(1H)-PYRIDONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USE AS DRUGS | GOEDECKE AG (DE) | 2000-01-05 | — | — | EP | claimed |
| US-12570684-B2 | DPAGT1 inhibitors of capuramycin analogues and their antimigratory activities of solid tumors | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2026-03-10 | — | — | US | disclosed |
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-11970448-B2 | Monomers capable of dimerizing in an aqueous solution, and methods of using same | CORNELL UNIVERSITY (US) | 2024-04-30 | — | — | US | disclosed |
| US-20230340006-A1 | DPAGT1 INHIBITORS OF CAPURAMYCIN ANALOGUES AND THEIR ANTIMIGRATORY ACTIVITIES OF SOLID TUMORS | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2023-10-26 | — | — | US | disclosed |
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ALTAVANT SCIENCES GMBH | 2023-09-19 | — | — | US | disclosed |
| US-20230010299-A1 | HETEROCYCLIC TRPML1 AGONISTS | LIBRA THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
| US-20220315548-A1 | SMALL MOLECULE AGONISTS OF MUCOLIPIN 1 AND USES THEREOF | NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES | 2022-10-06 | — | — | US | disclosed |
| US-20210276988-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2021-09-09 | — | — | US | disclosed |
| US-20210205305-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2021-07-08 | — | — | US | disclosed |
| US-20060135773-A1 | Trisubstituted nitrogen modulators of tyrosine phosphatases | METABASIS THERAPEUTICS, INC. | 2006-06-22 | — | — | US | disclosed |
| US-7041830-B2 | Process for preparing (RS) 3-methyl-1-(2-piperidinyl phenyl) butyl amine | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2006-05-09 | — | — | US | disclosed |
| US-20060052374-A1 | Amino-tetrazole analogues and methods of use | ABBVIE INC. | 2006-03-09 | — | — | US | disclosed |
| WO-2006009876-A2 | TRISUBSTITUTED NITROGEN MODULATORS OF TYROSINE PHOSPHATASES | CENGENT THERAPEUTICS, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
| US-20060004013-A1 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; 3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42; low hygroscopicity; good solubility | EISAI CO., LTD. | 2006-01-05 | — | — | US | disclosed |
| WO-2005095343-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2005-10-13 | — | — | WO | disclosed |
| US-20050080258-A1 | Pyridine and pyrimidine derivatives | GENTEX CORPORATION | 2005-04-14 | — | — | US | disclosed |
| US-20040192921-A1 | Process for preparing (RS) 3-methyl-1-(2-piperidinyl phenyl) butyl amine | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH | 2004-09-30 | — | — | US | disclosed |
| EP-1448555-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES | Celltech R & D Limited (GB) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003045941-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES | CELLTECH R & D LIMITED (GB) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11970448-B2 | Monomers capable of dimerizing in an aqueous solution, and methods of using same | CALCOCO2, MDN1, MBNL1 | NCF1 202/4885KEAP1 4353/4885MAPK1 1503/4885 |
| US-20040192921-A1 | Process for preparing (RS) 3-methyl-1-(2-piperidinyl phenyl) butyl amine | GPR119, GLP1R, IRS1 | NCF1 4334/4885KEAP1 1440/4885MAPK1 269/4885 |
| US-20220315548-A1 | SMALL MOLECULE AGONISTS OF MUCOLIPIN 1 AND USES THEREOF | MCOLN1, MCOLN2, MCOLN3 | NCF1 1669/4885KEAP1 3912/4885MAPK1 1005/4885 |
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | NR3C1, NR3C2, NR4A1 | NCF1 1648/4885KEAP1 3435/4885MAPK1 2366/4885 |
| US-20210205305-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | NCF1 2811/4885KEAP1 508/4885MAPK1 1325/4885 |
| US-20060135773-A1 | Trisubstituted nitrogen modulators of tyrosine phosphatases | PTPA, PTPN1, PTPRS | NCF1 240/4885KEAP1 3626/4885MAPK1 944/4885 |
| US-20230340006-A1 | DPAGT1 INHIBITORS OF CAPURAMYCIN ANALOGUES AND THEIR ANTIMIGRATORY ACTIVITIES OF SOLID TUMORS | DPAGT1, DPM1, DIMT1 | NCF1 305/4885KEAP1 3189/4885MAPK1 2312/4885 |
| US-20210276988-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | NR3C1, NR3C2, NR4A1 | NCF1 1648/4885KEAP1 3435/4885MAPK1 2366/4885 |
| US-12570684-B2 | DPAGT1 inhibitors of capuramycin analogues and their antimigratory activities of solid tumors | DPAGT1, MAGT1, DAD1 | NCF1 1684/4885KEAP1 2731/4885MAPK1 951/4885 |
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | NCF1 2811/4885KEAP1 508/4885MAPK1 1325/4885 |
| US-20060052374-A1 | Amino-tetrazole analogues and methods of use | P2RX7, P2RX2, P2RX3 | NCF1 2200/4885KEAP1 3617/4885MAPK1 3144/4885 |
| US-20230010299-A1 | HETEROCYCLIC TRPML1 AGONISTS | TRPM7, TRPM2, TRPM5 | NCF1 2001/4885KEAP1 1775/4885MAPK1 465/4885 |
| US-20060004013-A1 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; 3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42; low hygroscopicity; good solubility | PSEN1, APP, BACE1 | NCF1 3723/4885KEAP1 2680/4885MAPK1 58/4885 |
| US-20050080258-A1 | Pyridine and pyrimidine derivatives | ROR1, MAPK1, IRAK1 | NCF1 1701/4885KEAP1 1168/4885MAPK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.